Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed
to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab
plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and
high-risk patients with newly-diagnosed DLBCL